Chinook Therapeutics (KDNY) Stock Price, News & Analysis

Company Overview

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington. As of August 11, 2023, Chinook Therapeutics, Inc. operates as a subsidiary of Novartis AG.

Key Stats

• Today's Range: $40.39 to $40.39
• 50-Day Range: $38.66 to $40.39
• 52-Week Range: $18.34 to $40.51
• Volume: N/A
• Average Volume: 1.19 million shs
• Market Capitalization: $2.90 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Chinook Therapeutics Stock Analysis - MarketRank™

Chinook Therapeutics scored higher than 14% of companies evaluated by MarketBeat, and ranked 910th out of 948 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Chinook Therapeutics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Chinook Therapeutics are expected to decrease in the coming year, from ($3.30) to ($3.50) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Chinook Therapeutics is -11.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Chinook Therapeutics is -11.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Chinook Therapeutics has a P/B Ratio of 5.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for KDNY.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Chinook Therapeutics does not currently pay a dividend.

Dividend Growth

Chinook Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.06

Short Interest

There is no current short interest data available for KDNY.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for KDNY on MarketBeat in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Chinook Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.79% of the stock of Chinook Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

95.15% of the stock of Chinook Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

KDNY Stock Analysis - Frequently Asked Questions

How were Chinook Therapeutics' earnings last quarter?

Chinook Therapeutics, Inc. (NASDAQ:KDNY) posted its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.85) EPS for the quarter, missing analysts' consensus estimates of ($0.82) by $0.03. The firm's quarterly revenue was down 32.2% compared to the same quarter last year.

What other stocks do shareholders of Chinook Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Chinook Therapeutics investors own include Advanced Micro Devices (AMD), Meta Platforms (META), NIO (NIO), Ovintiv (OVV), Plug Power (PLUG), AMC Entertainment (AMC) and Applied Materials (AMAT).

Company Calendar

• Last Earnings: 5/09/2023
• Today: 10/16/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:KDNY
• CIK: 1435049
• Web: chinooktx.com
• Phone: (206) 485-7241
• Fax: N/A
• Employees: 214
• Year Founded: 2019

Profitability

• EPS (Trailing Twelve Months): ($3.52)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$187.87 million
• Net Margins: -4,199.93%
• Pretax Margin: -4,115.56%
• Return on Equity: -58.28%
• Return on Assets: -44.72%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.82
• Quick Ratio: 5.82

Sales & Book Value

• Annual Sales: $6.13 million
• Price / Sales: 473.15
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.91 per share
• Price / Book: 5.85

Miscellaneous

• Outstanding Shares: 71,810,000
• Free Float: 59,749,000
• Market Cap: $2.90 billion
• Optionable: Optionable
• Beta: 0.34